Compare Biocon Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DIVIS LABORATORIES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DIVIS LABORATORIES BIOCON /
DIVIS LABORATORIES
 
P/E (TTM) x 17.0 32.7 52.1% View Chart
P/BV x 2.6 7.4 35.8% View Chart
Dividend Yield % 0.4 0.6 72.1%  

Financials

 BIOCON    DIVIS LABORATORIES
EQUITY SHARE DATA
    BIOCON
Mar-18
DIVIS LABORATORIES
Mar-18
BIOCON /
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1881,142 104.0%   
Low Rs305533 57.2%   
Sales per share (Unadj.) Rs68.7146.6 46.9%  
Earnings per share (Unadj.) Rs7.633.0 22.9%  
Cash flow per share (Unadj.) Rs14.038.4 36.4%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.11.2 11.2%  
Book value per share (Unadj.) Rs86.3222.8 38.7%  
Shares outstanding (eoy) m600.00265.47 226.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.95.7 190.1%   
Avg P/E ratio x98.925.3 390.0%  
P/CF ratio (eoy) x53.421.8 245.0%  
Price / Book Value ratio x8.63.8 230.0%  
Dividend payout %13.230.3 43.7%   
Avg Mkt Cap Rs m447,900222,318 201.5%   
No. of employees `0006.110.8 57.1%   
Total wages/salary Rs m9,3114,561 204.2%   
Avg. sales/employee Rs Th6,705.83,616.0 185.5%   
Avg. wages/employee Rs Th1,514.2423.8 357.3%   
Avg. net profit/employee Rs Th736.9814.9 90.4%   
INCOME DATA
Net Sales Rs m41,23438,915 106.0%  
Other income Rs m2,0621,134 181.8%   
Total revenues Rs m43,29640,049 108.1%   
Gross profit Rs m8,29112,617 65.7%  
Depreciation Rs m3,8511,425 270.3%   
Interest Rs m61513 4,624.1%   
Profit before tax Rs m5,88712,313 47.8%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5693,543 44.3%   
Profit after tax Rs m4,5318,770 51.7%  
Gross profit margin %20.132.4 62.0%  
Effective tax rate %26.728.8 92.6%   
Net profit margin %11.022.5 48.8%  
BALANCE SHEET DATA
Current assets Rs m41,48645,351 91.5%   
Current liabilities Rs m21,4136,507 329.1%   
Net working cap to sales %48.799.8 48.8%  
Current ratio x1.97.0 27.8%  
Inventory Days Days64127 50.5%  
Debtors Days Days9495 99.0%  
Net fixed assets Rs m50,66121,160 239.4%   
Share capital Rs m3,000531 565.1%   
"Free" reserves Rs m48,80858,625 83.3%   
Net worth Rs m51,80859,156 87.6%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89767,832 147.3%  
Interest coverage x10.6926.8 1.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.6 71.9%   
Return on assets %5.212.9 39.8%  
Return on equity %8.714.8 59.0%  
Return on capital %9.620.8 46.2%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m12,05832,359 37.3%   
Fx outflow Rs m7,3489,042 81.3%   
Net fx Rs m4,71023,317 20.2%   
CASH FLOW
From Operations Rs m6,6217,759 85.3%  
From Investments Rs m-6,840-4,783 143.0%  
From Financial Activity Rs m-2,397-3,142 76.3%  
Net Cashflow Rs m-2,612-166 1,573.5%  

Share Holding

Indian Promoters % 40.4 52.0 77.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.8 71.2%  
FIIs % 10.7 19.0 56.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.2 115.7%  
Shareholders   109,995 31,796 345.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms Over 1,900 Points after Government Slashes Corporate Tax Rates(12:30 pm)

Share markets in India jumped sharply after FM Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 20, 2019 03:27 PM

TRACK BIOCON

BIOCON - DR. DATSONS LABS COMPARISON

COMPARE BIOCON WITH

MARKET STATS